Evidence map›Paper›PMID 31097023›Full record

ArticleTrials2019

Protocol for a randomised controlled trial to evaluate the effectiveness of improving tuberculosis patients' treatment adherence via electronic monitors and an app versus usual care in Tibet.

Xiaolin Wei, Joseph Paul Hicks, Pande Pasang, Zhitong Zhang, Victoria Haldane, Xiaoqiu Liu, Tingting Yin, Lixia Wang, Dachun Shi, Shiliang Ge and 3 more

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
5.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 4 countries.

Xiaolin WeiDalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-3076-2650
Joseph Paul HicksNuffield Centre for International Health and Development, University of Leeds, Leeds, UK.
Pande PasangShigatse Centre for Disease Control and Prevention, 7 Keji Road, Samzhubze District, Shigatse, Tibet, China.
Zhitong ZhangShigatse Centre for Disease Control and Prevention, 7 Keji Road, Samzhubze District, Shigatse, Tibet, China.
Victoria HaldaneDalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Xiaoqiu LiuChina National Centre for Tuberculosis Prevention and Control, China National Centre for Disease Control and Prevention, Beijing, China.
Tingting YinWeifang Medical College, Weifang, Shandong, China.
Lixia WangChina National Centre for Tuberculosis Prevention and Control, China National Centre for Disease Control and Prevention, Beijing, China.
Dachun ShiShigatse Centre for Disease Control and Prevention, 7 Keji Road, Samzhubze District, Shigatse, Tibet, China.
Shiliang GeDalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
John WalleyNuffield Centre for International Health and Development, University of Leeds, Leeds, UK.
Ross UpshurDalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Jun HuShigatse Centre for Disease Control and Prevention, 7 Keji Road, Samzhubze District, Shigatse, Tibet, China. sunnyhj@163.com.
Chinese Center For Disease Control and Prevention · CNUniversity of Toronto · CAUniversity of Leeds · GBWeifang Medical University · CN

Funding

TB REACH STBP/TBREACH/GSA/W6-5
6 · The paper itself

Abstract

backgroundTreatment non-adherence is a serious challenge to effective tuberculosis (TB) control in Tibet. In this study we will pilot and evaluate the effectiveness of using new electronic monitors (e-monitors) and a smartphone app to improve treatment adherence among new pulmonary TB patients in Tibet.

methodsWe will use a multicentre, parallel-group, individually randomised controlled, superiority trial with blinded outcome evaluation and unblinded treatment. We will randomise new pulmonary TB outpatients (aged ≥ 15 years old and free from communication impairment) from Shigatse, Tibet to either the intervention or control arm in a 1:1 ratio at the time of their diagnosis. All patients will be treated according to the World Health Organisation standard 6-month TB treatment regimen and the China National TB programme guidelines. Intervention arm patients will be given their medication via e-monitors that have automatic voice reminders, and record medication adherence data and share it with health staff via Cloud connection. Intervention patients will also be encouraged to receive smartphone-based video-observed treatment if their adherence is problematic. Control arm patients will receive their medication in e-monitors that will collect medication adherence history, but will have their reminder function deactivated and are not linked to the app. The primary outcome is the rate of poor adherence, measured monthly during treatment as a binary indicator where poor adherence means missing ≥ 20% of doses in a month. We will conduct a qualitative process evaluation to explore operational questions regarding acceptability, cultural appropriateness and burden of technology use, as well as a cost-effectiveness analysis and an analysis of the long-term effects of the intervention on TB control. DISCUSSION: Our study is one of the first trials to evaluate the use of e-monitors and smartphone apps for customised treatment support in low- and middle-income countries (LMICs). All intervention activities are designed to be embedded into routine TB care with strong local ownership. Through the trial we intend to understand the feasibility of our intervention, its effectiveness, its cost-effectiveness and its long-term impacts to inform future scale-up in remote areas of China and other LMICs.

trial registrationCurrent Controlled Trials, ID: ISRCTN52132803 . Registered on 9 November 2018.

Indexed as

Antitubercular AgentsMedication AdherenceReminder SystemsTuberculosisData Interpretation, StatisticalEquivalence Trials as TopicHumansMulticenter Studies as TopicOutcome Assessment, Health CareRandomized Controlled Trials as TopicSample SizeText MessagingTibetAntitubercular AgentsMhealthRandomised controlled trialTibetTreatment adherenceTuberculosis

Identifiers

PMID31097023
PMCPMC6521492
OpenAlexW2945844404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.